Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II randomized double-blind study of recombinant botulinum toxin type A DJ-01 for moderate-to-severe glabellar lines
CTR20251850Phase 2Completed
- Sponsor
- Suzhou Dejin Biopharmaceuticals
- Start
- Jun 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of DJ-01 in glabellar furrowing, sponsored by Suzhou Dejin Biopharmaceuticals. Started Jun 2025; status: completed.
02
Drugs
DJ-01
03
Conditions
glabellar furrowing
Beyond the preview
Go deeper on CTR20251850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251850.